Age, Biography and Wiki

David Boulware (David R Boulware) was born on 1974 in USA, is a researcher. Discover David Boulware's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is He in this year and how He spends money? Also learn how He earned most of networth at the age of 49 years old?

Popular As David R Boulware
Occupation Physician infectious diseases (medical specialty)
Age 49 years old
Zodiac Sign
Born 1974
Birthday 1974
Birthplace United States
Nationality United States

We recommend you to check the complete list of Famous People born on 1974. He is a member of famous researcher with the age 49 years old group.

David Boulware Height, Weight & Measurements

At 49 years old, David Boulware height not available right now. We will update David Boulware's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.

Physical Status
Height Not Available
Weight Not Available
Body Measurements Not Available
Eye Color Not Available
Hair Color Not Available

Dating & Relationship status

He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.

Family
Parents Not Available
Wife Not Available
Sibling Not Available
Children Not Available

David Boulware Net Worth

His net worth has been growing significantly in 2022-2023. So, how much is David Boulware worth at the age of 49 years old? David Boulware’s income source is mostly from being a successful researcher. He is from United States. We have estimated David Boulware's net worth , money, salary, income, and assets.

Net Worth in 2023 $1 Million - $5 Million
Salary in 2023 Under Review
Net Worth in 2022 Pending
Salary in 2022 Under Review
House Not Available
Cars Not Available
Source of Income researcher

David Boulware Social Network

Instagram
Linkedin
Twitter
Facebook
Wikipedia
Imdb

Timeline

2021

Boulware served as senior investigator on other trials testing early treatments for covid-19 including the TogetherTrial ivermectin;, which demonstrated that ivermectin did not have a clinical benefit for early COVID-19. University of Minnesota's COVID-Out randomized trial testing metformin, ivermectin, and fluvoxamine. The Covid-Out trial reported a 42% reduction in COVID-related emergency room visits and hospitalizations with the use of metformin. In December 2021, Boulware took the initiate to apply to the U.S. FDA for an Emergency Use Authorization for fluvoxamine 100 mg twice daily.

2020

Boulware's team rapidly launched a series of three U.S. nationwide randomized clinical trials testing hydroxychloroquine for post-exposure prophylaxis, early treatment, and pre-exposure prophylaxis for prevention of COVID-19 on March 17, 2020. These were among the first U.S. trials to be launched. The pre-exposure prophylaxis trial was reported June 3, 2020 showing that taking hydroxychloroquine was not effective at preventing COVID-19. As described, "To say that the recruitment of this post-exposure prophylaxis trial was innovative hardly gives the methods enough credit." These trials were pioneering for being remote internet-based randomzied clinical trials.

While pre-exposure prophylaxis with hydroxychloroquine for prevention was promoted on May 18, 2020, the subsequent randomized trial did not show any benefit.